Report: Current Stock Reports

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS
February 14, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
February 9, 2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
February 7, 2024

Achievement of the second milestone under license agreement with Exelixis Inc.
February 5, 2024

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 5, 2024

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax
January 31, 2024

Registration of series K subscription warrants of the Company with the National Depository for Securities
January 31, 2024

Publication dates for periodic reports in 2024
January 18, 2024

Take-up of series K subscription warrants by the European Investment Bank
January 18, 2024

Resignation of a member of the Company’s Supervisory Board from his position
January 3, 2024

Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update
December 11, 2023

Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting
December 11, 2023

Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023
December 7, 2023

Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting
November 2, 2023

Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update
October 23, 2023

Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes
October 20, 2023

RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023
October 16, 2023

Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 16, 2023

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
October 4, 2023

Conclusion of an amendment to global License Agreement with Menarini Group
September 14, 2023